Metabolic reprogramming in the CLL TME; potential for new therapeutic targets [0.03%]
CLL肿瘤微环境中的代谢重组；对新治疗靶点的探索可能性
Helga Simon-Molas,Chiara Montironi,Anna Kabanova et al.
Helga Simon-Molas et al.
Chronic lymphocytic leukemia (CLL) cells circulate between peripheral (PB) blood and lymph node (LN) compartments, and strictly depend on microenvironmental factors for proliferation, survival and drug resistance. All cancer cells display m...
Clonal hematopoiesis [0.03%]
克隆性造血干细胞疾病
Jaroslaw P Maciejewski
Jaroslaw P Maciejewski
Luca Guarnera,Babal K Jha
Luca Guarnera
Loss of function TET2 mutation (TET2MT) is one of the most frequently observed lesions in clonal hematopoiesis (CH). TET2 a member TET-dioxygenase family of enzymes that along with TET1 and TET3, progressively oxidize 5-methyl cytosine (mC)...
Clonal hematopoiesis in the setting of hematopoietic cell transplantation [0.03%]
造血细胞移植过程中发生的克隆性造血现象
Christopher J Gibson,R Coleman Lindsley,Lukasz P Gondek
Christopher J Gibson
Clonal hematopoiesis (CH) in autologous transplant recipients and allogeneic transplant donors has genetic features and clinical associations that are distinct from each other and from non-cancer populations. CH in the setting of autologous...
Ashwin Kishtagari,Robert W Corty,Valeria Visconte
Ashwin Kishtagari
Clonal hematopoiesis (CH) has been associated with aging, occurring in about 10% of individuals aged >70 years, and immune dysfunction. Aged hematopoietic stem and progenitor cells exhibit pathological changes in immune function and activat...
Abhay Singh,Suresh Balasubramanian
Abhay Singh
The intricate interplay between Clonal Hematopoiesis (CH) and the repercussions of cancer therapies has garnered significant research focus in recent years. Previously perceived as an age-related phenomenon, CH is now closely linked to infl...
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities [0.03%]
力求首次治愈DLBCL的老年患者和/或合并症患者
Elizabeth A Brem,Laurie H Sehn
Elizabeth A Brem
Diffuse large B-cell lymphoma (DLBCL) is an aggressive but often curable malignancy. Older patients, especially those 80 years and older, have poor outcomes compared to those < 60, likely due to a number of reasons including disease biology...
Amit Sud,Erin M Parry,Catherine J Wu
Amit Sud
Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's syndrome (RS) provides a comprehensive model of cancer evolution, notab...
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS [0.03%]
巴别塔的首字母缩写？MGUS/MBL/CHIP/TCUS的阴霾之地
Carlos Bravo-Perez,Carmelo Gurnari
Carlos Bravo-Perez
With the advent of outperforming and massive laboratory tools, such as multiparameter flow cytometry and next-generation sequencing, hematopoietic cell clones with putative abnormalities for a variety of blood malignancies have been appreci...
Second-line treatment of diffuse large B-cell lymphoma: Evolution of options [0.03%]
弥漫性大B细胞淋巴瘤的二线治疗：治疗选择的变化发展
N Fabbri,A Mussetti,A Sureda
N Fabbri
In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy. However, 30%-40% relapse after initial response to first-line th...